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constructed from peripheral blood lymphocytes of eight
patients infected with Plasmodium falciparum and screened
for the production of human monoclonal antibody Fab frag-
ments to the C terminal 19-kDa fragment of P. falciparum
merozoite surface protein 1 (MSP-119). Three Fab clones rec-
ognized recombinant MSP-119 under nonreducing conditions.
Indirect immunoﬂuorescence microscopy demonstrated that
three Fab clones stained the surface of late tropho-
zoites/schizonts and merozoites. The dissociation constants
of these Fab fragments to recombinant MSP-119 ranged from
1.09× 10−9 to 2.66× 10−9 M. In order to improve the bind-
ing afﬁnity of the Fab fragments, we modiﬁed the single
amino acid in the third complementary-determining regions
of Fab heavy and light chains by using recombination PCR.
Tyr92 or Ile97 in the light chain and Val101 or Trp107 in
the heavy chain were selected and modiﬁed. While effec-
tive replacement at Tyr92 or Val101was not found, Ile97 in
the light chain and Trp107 in the heavy chain were possi-
bly substituted with Gly, Leu, Glu, Ala or Ser, and Arg or
Ser, respectively. Fabs with Ile97Leu and Trp107Ser exhibited
the improved afﬁnity compared with the original Fab. Our
study shows that the combinatorial immunoglobulin gene
library derived from malaria patients provides a powerful
tool for producing high-afﬁnity human antibodies speciﬁc for
P. falciparum.
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Background: Anti-malarial drug resistance is a challeng-
ing problem for the global health community including
sub-Saharan Africa. Resistance to chloroquine (CQ)-ﬁrst
emerging in the 1960s-has steadily increased, and only
negligible susceptibility remains in much of the world.
Sulphadoxine/pyrimethamine (SP) replaced CQ as the
ﬁrst line therapeutic in Kenya for uncomplicated malaria
in 1998. During this’s study’s time period, 2003—2005,
anecdotal evidence indicated frequent SP treatment
failure.
Methods: To determine the malarial resistance patterns
to CQ and SP in two contrasting regions of Kenya, speci-
mens were collected from symptomatic volunteers in Malindi
and Busia. These towns represent coastal and western Kenya
respectively-the two regions of highest malaria transmission
in Kenya. DNA was isolated, and point speciﬁc polymor-
phisms known to confer resistance, Pfdhfr, Pfdhps, Pfmdr1,
and Pfcrt, were genotyped.
Results: There was over 90 percent mutation of the Pfcrt
gene (K76 locus) at both study sites which is consistent
with high CQ resistance. Likewise, SP demonstrated greater
than 75% mutation at all important resistance loci at both
sites. Speciﬁcally, a ‘‘quintuple mutant’’ (triple mutation
in Pfdhfr, Asn51Ile, Cys59Arg, Ser108Asn and Ala437Gly, Lys,
Leu540Glu mutations in Pfdhps) were detected in Malindi
and Busia.
Conclusion: Signiﬁcant resistance to CQ and SP in both
regions was observed. CQ resistance persisted despite a
decrease in drug pressure secondary to the national formu-
lary change in 1998 though it is likely that CQ is still widely
available and used as a self-medication. The discovery of
the quintuplemutation implies near-total SP resistance. This
ﬁnding was signiﬁcant because SP was the primary treatment
modality in Kenya at the time of the study, and incidentally,
this research subsequently played a signiﬁcant role in the
Health Ministry’s adoption of artemisinin-based antimalari-
als in 2005.
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Background: Pfcrt and Pfmdr1 mutations have been
reported to be associated with chloroquine resistance, but
these reports have been inconsistent. Red cell factors,
sickle cell trait, ABO blood group antigens and glucose-
6-phosphate dehydrogenase (G6PD) deﬁciency are known
to confer some degree of resistance against malaria para-
site infection but their interplay with CQ resistance is yet
unknown. This study therefore aims at evaluating the cor-
relation of CQ resistance with Pfmdr1 mutation and certain
host factors in humans.
Methods: One hundred and twenty patients (1—15yrs)
with acute uncomplicated falciparum malaria were enrolled
into the study. They were administered standard doses
of CQ and followed up for parasitological and clini-
cal response for 14 days. Thick and thin blood ﬁlms
as well as ﬁlter paper blood samples were obtained
from patients before enrolment and during follow up.
Blood samples were collected in EDTA bottles for assess-
ment of haematological parameters. DNA was extracted
from ﬁlter paper using the methanol ﬁxation method and
used for Pfmdr1 and msp1 analyses by polymerase chain
reaction.
Results: Seventy patients were followed up to day 14.53%
of the patients were cured, with a 47% failure rate to
CQ. Although Pfmdr1Y86 was detected in majority of the
patients (19/33) with clinical failure, this was not statisti-
cally signiﬁcant (p > 0.05). 88% of the clinical failures was
due to recrudescence and this was highly signiﬁcant with
treatment outcome (p = 0.000). No signiﬁcant association
was found between Pfmdr1 alleles and red cell factors. How-
ever, individuals with HbAA were found to be 2.3 times more
likely to develop resistance to CQ treatment compared to
those having HbAS.
Conclusion: In conclusion, the prevalence of CQ resis-
tance and Pfmdr1Y86 mutation was high in this malaria
endemic setting. There was no clear inﬂuence of ABO, G6PD
